HENLIUS (02696) Surges Over 5% Intraday as Company Unveils First Phase II Clinical Data for PD-L1 ADC in Esophageal Squamous Cell Carcinoma

Stock News01-08

HENLIUS (02696) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.39%, trading at HKD 66.65, with a turnover of HKD 23.9053 million. On the news front, according to reports from pharmaceutical research networks, the 2026 ASCO GI conference is scheduled to take place from January 8 to January 10, 2026, with the official release of abstract contents for this Gastrointestinal Cancers Symposium. Notably, HENLIUS has for the first time disclosed clinical data from its Phase II study of the PD-L1 ADC drug candidate HLX43 for the treatment of recurrent/metastatic esophageal squamous cell carcinoma (ESCC). HLX43 is a novel ADC drug targeting PD-L1, which combines the dual mechanisms of immune checkpoint inhibition and cytotoxic effects. Its Phase I clinical trial has already demonstrated promising efficacy and a favorable safety profile in patients who did not respond to prior immunotherapy. This Phase II study is designed to evaluate the efficacy and safety of HLX43 in patients with previously treated recurrent or metastatic esophageal squamous cell carcinoma.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118913475?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 11:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118913475","market":"sg","top_or_hot":-1,"title":"HENLIUS (02696) Surges Over 5% Intraday as Company Unveils First Phase II Clinical Data for PD-L1 ADC in Esophageal Squamous Cell Carcinoma","media":"Stock News","content":"<p>HENLIUS (02696) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.39%, trading at HKD 66.65, with a turnover of HKD 23.9053 million.\nOn the news front, according to reports from pharmaceutical research networks, the 2026 ASCO GI conference is scheduled to take place from January 8 to January 10, 2026, with the official release of abstract contents for this Gastrointestinal Cancers Symposium.\nNotably, HENLIUS has for the first time disclosed clinical data from its Phase II study of the PD-L1 ADC drug candidate HLX43 for the treatment of recurrent/metastatic esophageal squamous cell carcinoma (ESCC).\nHLX43 is a novel ADC drug targeting PD-L1, which combines the dual mechanisms of immune checkpoint inhibition and cytotoxic effects. Its Phase I clinical trial has already demonstrated promising efficacy and a favorable safety profile in patients who did not respond to prior immunotherapy.\nThis Phase II study is designed to evaluate the efficacy and safety of HLX43 in patients with previously treated recurrent or metastatic esophageal squamous cell carcinoma.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENLIUS (02696) Surges Over 5% Intraday as Company Unveils First Phase II Clinical Data for PD-L1 ADC in Esophageal Squamous Cell Carcinoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENLIUS (02696) Surges Over 5% Intraday as Company Unveils First Phase II Clinical Data for PD-L1 ADC in Esophageal Squamous Cell Carcinoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-08 11:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENLIUS (02696) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.39%, trading at HKD 66.65, with a turnover of HKD 23.9053 million.\nOn the news front, according to reports from pharmaceutical research networks, the 2026 ASCO GI conference is scheduled to take place from January 8 to January 10, 2026, with the official release of abstract contents for this Gastrointestinal Cancers Symposium.\nNotably, HENLIUS has for the first time disclosed clinical data from its Phase II study of the PD-L1 ADC drug candidate HLX43 for the treatment of recurrent/metastatic esophageal squamous cell carcinoma (ESCC).\nHLX43 is a novel ADC drug targeting PD-L1, which combines the dual mechanisms of immune checkpoint inhibition and cytotoxic effects. Its Phase I clinical trial has already demonstrated promising efficacy and a favorable safety profile in patients who did not respond to prior immunotherapy.\nThis Phase II study is designed to evaluate the efficacy and safety of HLX43 in patients with previously treated recurrent or metastatic esophageal squamous cell carcinoma.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PD","symbol_name":"PagerDuty, Inc.","start_time":0,"source_url":"","article_id":"1118913475","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118913475","pubTimestamp":1767842659,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (02696) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.39%, trading at HKD 66.65, with a turnover of HKD 23.9053 million. On the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PD":"PagerDuty, Inc.","BK4023":"应用软件","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK1161":"生物科技","ADC":"艾格里房产","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","02696":"复宏汉霖","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币"},"translate_title":"复宏汉霖(02696)盘中大涨超5%，公司公布PD-L1 ADC治疗食管鳞癌首个II期临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"02696":1,"ADC":1},"content_text":"HENLIUS (02696) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.39%, trading at HKD 66.65, with a turnover of HKD 23.9053 million.\nOn the news front, according to reports from pharmaceutical research networks, the 2026 ASCO GI conference is scheduled to take place from January 8 to January 10, 2026, with the official release of abstract contents for this Gastrointestinal Cancers Symposium.\nNotably, HENLIUS has for the first time disclosed clinical data from its Phase II study of the PD-L1 ADC drug candidate HLX43 for the treatment of recurrent/metastatic esophageal squamous cell carcinoma (ESCC).\nHLX43 is a novel ADC drug targeting PD-L1, which combines the dual mechanisms of immune checkpoint inhibition and cytotoxic effects. Its Phase I clinical trial has already demonstrated promising efficacy and a favorable safety profile in patients who did not respond to prior immunotherapy.\nThis Phase II study is designed to evaluate the efficacy and safety of HLX43 in patients with previously treated recurrent or metastatic esophageal squamous cell carcinoma.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118913475","isCrawlerRequest":true}